JP2011133396A - 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 - Google Patents
活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 Download PDFInfo
- Publication number
- JP2011133396A JP2011133396A JP2009294107A JP2009294107A JP2011133396A JP 2011133396 A JP2011133396 A JP 2011133396A JP 2009294107 A JP2009294107 A JP 2009294107A JP 2009294107 A JP2009294107 A JP 2009294107A JP 2011133396 A JP2011133396 A JP 2011133396A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- partial thromboplastin
- activated partial
- plasma
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 158
- 230000023555 blood coagulation Effects 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000003130 blood coagulation factor inhibitor Substances 0.000 title claims abstract description 35
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 title claims abstract description 32
- 108010000499 Thromboplastin Proteins 0.000 title claims abstract description 32
- 102000002262 Thromboplastin Human genes 0.000 title claims abstract description 32
- 230000036961 partial effect Effects 0.000 title claims abstract description 32
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229920000669 heparin Polymers 0.000 claims abstract description 41
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 39
- 229960002897 heparin Drugs 0.000 claims abstract description 38
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 30
- 239000012190 activator Substances 0.000 claims abstract description 25
- 238000005259 measurement Methods 0.000 claims description 110
- 238000012360 testing method Methods 0.000 claims description 110
- 239000003795 chemical substances by application Substances 0.000 claims description 47
- 108090000778 Platelet factor 4 Proteins 0.000 claims description 35
- 102000004211 Platelet factor 4 Human genes 0.000 claims description 35
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 30
- 230000015271 coagulation Effects 0.000 claims description 12
- 238000005345 coagulation Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 11
- 206010053567 Coagulopathies Diseases 0.000 claims description 8
- 230000035602 clotting Effects 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 5
- 229920002079 Ellagic acid Polymers 0.000 claims description 5
- 229960002852 ellagic acid Drugs 0.000 claims description 5
- 235000004132 ellagic acid Nutrition 0.000 claims description 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 239000008119 colloidal silica Substances 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- 208000013633 acquired hemophilia Diseases 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 238000007711 solidification Methods 0.000 claims description 3
- 230000008023 solidification Effects 0.000 claims description 3
- 230000000937 inactivator Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- 239000011575 calcium Substances 0.000 description 18
- 229960005069 calcium Drugs 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 18
- 239000000872 buffer Substances 0.000 description 10
- 238000000691 measurement method Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 5
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 description 1
- 239000001427 calcium tartrate Substances 0.000 description 1
- 235000011035 calcium tartrate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 208000014763 coagulation protein disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009294107A JP2011133396A (ja) | 2009-12-25 | 2009-12-25 | 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 |
| US12/976,681 US8357539B2 (en) | 2009-12-25 | 2010-12-22 | Activated partial thromboplastin time measuring reagent, activated partial thromboplastin time measuring method, and determination method for determining presence or absence of blood coagulation inhibitor |
| EP10196681A EP2339021A1 (fr) | 2009-12-25 | 2010-12-23 | Réactif de mesure du temps de thromboplastine partielle activée, procédé de mesure du temps de thromboplastine partielle activée et procédé de détermination de la présence ou de l'absence d'un inhibiteur de la coagulation du sang |
| CN2010106042495A CN102141570A (zh) | 2009-12-25 | 2010-12-24 | 活化部分凝血酶时间测定试剂、活化部分凝血酶时间测定法及判断有无抗凝血物质的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009294107A JP2011133396A (ja) | 2009-12-25 | 2009-12-25 | 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011133396A true JP2011133396A (ja) | 2011-07-07 |
Family
ID=43577347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009294107A Pending JP2011133396A (ja) | 2009-12-25 | 2009-12-25 | 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8357539B2 (fr) |
| EP (1) | EP2339021A1 (fr) |
| JP (1) | JP2011133396A (fr) |
| CN (1) | CN102141570A (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016136558A1 (fr) * | 2015-02-27 | 2016-09-01 | 学校法人東日本学園 | Procédé d'acquisition d'informations sur la cause de l'allongement de la durée de coagulation, et dispositif et programme permettant la mise en œuvre dudit procédé |
| CN114113641A (zh) * | 2021-10-28 | 2022-03-01 | 中科精瓒(武汉)医疗技术有限公司 | 一种活化凝血检测试剂及其制备方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014190954A (ja) | 2013-03-28 | 2014-10-06 | Sysmex Corp | 活性化部分トロンボプラスチン時間測定用試薬およびその利用 |
| SE540132C2 (sv) * | 2014-05-22 | 2018-04-10 | Zafena Ab | Analysmetod för bestämning av antikoagulanter i blod eller blodplasma |
| JP6499488B2 (ja) * | 2015-03-31 | 2019-04-10 | 学校法人東日本学園 | 凝固時間の測定方法、ループスアンチコアグラントの存否の判定方法及びループスアンチコアグラント検出用試薬キット |
| CN105603048B (zh) * | 2016-01-18 | 2017-05-31 | 青岛古高生物科技有限公司 | 含杨梅酮和咖啡酸的凝血酶原时间测定试剂及其制备方法 |
| CN107782680A (zh) * | 2016-08-26 | 2018-03-09 | 山东博科生物产业有限公司 | 一种稳定的抗肝素脂肪酶检测试剂盒 |
| CN106596981B (zh) * | 2016-12-09 | 2018-09-18 | 王清 | 一种用于测定凝血功能的试剂盒 |
| JP6837851B2 (ja) * | 2017-01-31 | 2021-03-03 | シスメックス株式会社 | 血液検体の判定方法、並びに血液検体の分析のための装置及びコンピュータプログラム |
| JP6873833B2 (ja) * | 2017-06-09 | 2021-05-19 | シスメックス株式会社 | 血液検体の判定方法、血液検体分析装置及びコンピュータプログラム |
| CN108956967A (zh) * | 2018-05-24 | 2018-12-07 | 天晴干细胞股份有限公司 | 一种用于细菌内毒素凝胶法检测血浆用的血浆稀释液试剂盒及其使用方法 |
| JP7153519B2 (ja) | 2018-09-28 | 2022-10-14 | シスメックス株式会社 | 凝固時間測定用試薬及びその製造方法、試薬キット及び凝固時間の測定方法 |
| CN110208513A (zh) * | 2019-07-03 | 2019-09-06 | 常熟常江生物技术有限公司 | 一种血液中肝素或肝素类物质的检测方法和试剂盒 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04350560A (ja) * | 1990-03-03 | 1992-12-04 | Behringwerke Ag | プロテインｓ活性の機能的測定方法 |
| JPH0643169A (ja) * | 1992-05-15 | 1994-02-18 | Immuno Ag | 内因性凝固系のイニシエーター |
| JP2003517610A (ja) * | 1999-12-15 | 2003-05-27 | ペンタファルム・リミテッド | 血液学的アッセイ及び試薬 |
| JP2005249778A (ja) * | 2004-02-06 | 2005-09-15 | Sysmex Corp | ループスアンチコアグラント検出試薬キット |
| JP2009058393A (ja) * | 2007-08-31 | 2009-03-19 | Sysmex Corp | 血液凝固測定用試薬及び血液凝固時間測定方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151192A (en) * | 1990-07-13 | 1992-09-29 | Pall Corporation | Method for removing heparin from blood or plasma |
| US5262325A (en) * | 1991-04-04 | 1993-11-16 | Ibex Technologies, Inc. | Method for the enzymatic neutralization of heparin |
| ATE177536T1 (de) * | 1993-06-30 | 1999-03-15 | Diagnostische Forsch Stiftung | Messung des aktivierten partiellen thromboplastinzeit (aptt) in einer einstufen- reaktion |
| ATE198772T1 (de) * | 1994-11-10 | 2001-02-15 | Dade Behring Marburg Gmbh | Verfahren zum spezifischen nachweis eines aktivierten gerinnungsfaktors v mit einer erhöhten stabilität gegenüber aktiviertem protein c |
| US20030143759A1 (en) * | 1995-10-20 | 2003-07-31 | Bjorn Dahlback | Assays for determining anticoagulant cofactor activity |
| CA2288058A1 (fr) * | 1997-04-23 | 1998-10-29 | Instrumentation Laboratory, S.P.A. | Reactif pour la determination du temps de prothrombine a base d'un facteur tissulaire recombine de lapin |
| US20040091952A1 (en) * | 2002-07-25 | 2004-05-13 | Sysmex Corporation | Reagent kit for detecting lupus anticoagulant |
-
2009
- 2009-12-25 JP JP2009294107A patent/JP2011133396A/ja active Pending
-
2010
- 2010-12-22 US US12/976,681 patent/US8357539B2/en not_active Expired - Fee Related
- 2010-12-23 EP EP10196681A patent/EP2339021A1/fr not_active Withdrawn
- 2010-12-24 CN CN2010106042495A patent/CN102141570A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04350560A (ja) * | 1990-03-03 | 1992-12-04 | Behringwerke Ag | プロテインｓ活性の機能的測定方法 |
| JPH0643169A (ja) * | 1992-05-15 | 1994-02-18 | Immuno Ag | 内因性凝固系のイニシエーター |
| JP2003517610A (ja) * | 1999-12-15 | 2003-05-27 | ペンタファルム・リミテッド | 血液学的アッセイ及び試薬 |
| JP2005249778A (ja) * | 2004-02-06 | 2005-09-15 | Sysmex Corp | ループスアンチコアグラント検出試薬キット |
| JP2009058393A (ja) * | 2007-08-31 | 2009-03-19 | Sysmex Corp | 血液凝固測定用試薬及び血液凝固時間測定方法 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6013004910; Ｅｖａ Ｍ． Ｊａｃｏｂｓｅｎ ｅｔ ａｌ．: 'Ｄｅｔｅｃｔｉｏｎ ａｎｄ ｑｕａｎｔｉｆｉｃａｔｉｏｎ ｏｆ ｌｕｐｕｓ ａｎｔｉｃｏａｇｕｌａｎｔｓ ｉｎ ｐｌａｓｍａ ｆｒｏｍ ｈｅｐａｒｉｎ ｔｒｅａｔｅｄ ｐａｔｉｅｎｔｓ， ｕｓｉｎｇ' ＴＨＲＯＭＢＯＳＩＳ ＪＯＵＲＮＡＬ Ｖｏｌ．４，Ｎｏ．１, 20060125, Ｐ．１-７ * |
| JPN6013004911; 香川和彦: '血液凝固補正試験' 検査と技術 Ｖｏｌ．３４，Ｎｏ．８, 20060801, Ｐ．７３５-７４２ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016136558A1 (fr) * | 2015-02-27 | 2016-09-01 | 学校法人東日本学園 | Procédé d'acquisition d'informations sur la cause de l'allongement de la durée de coagulation, et dispositif et programme permettant la mise en œuvre dudit procédé |
| JPWO2016136558A1 (ja) * | 2015-02-27 | 2017-12-07 | 学校法人東日本学園 | 凝固時間の延長原因に関する情報を取得する方法とそれを実施するための装置及びプログラム |
| CN114113641A (zh) * | 2021-10-28 | 2022-03-01 | 中科精瓒(武汉)医疗技术有限公司 | 一种活化凝血检测试剂及其制备方法 |
| CN114113641B (zh) * | 2021-10-28 | 2023-11-03 | 中科精瓒(武汉)医疗技术有限公司 | 一种活化凝血检测试剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8357539B2 (en) | 2013-01-22 |
| US20110159597A1 (en) | 2011-06-30 |
| EP2339021A1 (fr) | 2011-06-29 |
| CN102141570A (zh) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011133396A (ja) | 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 | |
| JP6025105B2 (ja) | ループスアンチコアグラント検出用血液凝固時間の測定方法 | |
| US5055412A (en) | Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same | |
| JP2014190954A (ja) | 活性化部分トロンボプラスチン時間測定用試薬およびその利用 | |
| ES2528592T3 (es) | Método para determinar la causa de la prolongación del tiempo de coagulación sanguínea | |
| KR20040040384A (ko) | 조직 인자에 기초한 프로트롬빈 시간 시약의 제조방법 | |
| CN107748267B (zh) | 一种测定活化部分凝血活酶时间（aptt）的试剂盒 | |
| EP3136105A1 (fr) | Réactif pour la mesure du temps partiel de thromboplastine activée, kit de réactif pour la mesure du temps partiel de thromboplastine activée, et procédé de mesure du temps partiel de thromboplastine activée | |
| JP6577778B2 (ja) | 凝固時間の測定方法およびその装置、凝固時間測定用試薬ならびに試薬キット | |
| CA2839117C (fr) | Methode pour la detection d'anticoagulants lupiques | |
| JPH05180835A (ja) | ループスアンチコアグラントの測定方法 | |
| BR102015005628A2 (pt) | composição, e, uso de ácido ferúlico | |
| CN112557665A (zh) | 一种狼疮抗凝物的确认试剂及其制备方法 | |
| JP2005156482A (ja) | 血液凝固能測定方法および血液凝固能測定用試薬 | |
| JP2017032344A (ja) | 凝固時間の測定方法およびその装置、凝固時間測定用試薬ならびに試薬キット | |
| JP4417269B2 (ja) | ループスアンチコアグラント検出試薬キット | |
| CN117031047A (zh) | 血小板聚集功能检测花生四烯酸试剂及其制备方法 | |
| CN116223821A (zh) | 血小板聚集功能检测试剂及其应用 | |
| JPH06324048A (ja) | 血液凝固能検査用試薬及び血液凝固能の検査方法 | |
| CN103649758B (zh) | 狼疮抗凝物的检测方法 | |
| M Albayaa | • Control of Oral Anticoagulant Therapy Using EDTA Plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110812 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130205 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130206 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130611 |